Find Academic Supervisors

Harris H. WangView profile

Associate Professor

• Systems Biology
• Synthetic Biology
• Genome Engineering
• +17 more

Harris H. Wang is an Associate Professor in the Department of Systems Biology and Department of Pathology and Cell Biology at Columbia University's Vagelos College of Physicians and Surgeons, where he also serves as Interim Chair of Systems Biology. He is affiliated with the Center for Computational Biology and Bioinformatics (C2B2) and the Integrated Program in Cellular, Molecular and Biomedical Studies (CMBS). B.S., Physics and Mathematics, MIT Ph.D., Biophysics, Harvard University Dr. Wang's research lies at the intersection of systems and synthetic biology, focusing on developing foundational technologies for genome engineering, microbiome manipulation, and synthetic genomics. His lab pioneers methods such as MAGE, MAGIC, CAST, and CAMII to enable high-throughput genetic manipulation, in situ microbiome engineering, and AI-driven microbial culturomics. Key research themes include understanding microbial community dynamics, engineering cellular memory systems, designing biocontained genetic circuits, and applying synthetic biology to human health challenges in personalized medicine and infectious disease. His recent publications reveal a strong trend in spatial and functional metagenomics, CRISPR-based microbiome editing, and synthetic biology tools for data storage and genetic stability. The articles span high-impact journals like Nature , Science , and Nature Biotechnology , reflecting his leadership in developing scalable, programmable biological systems. Scientific Awards: NIH Director’s Early Independence Award Forbes 30 Under 30 in Science Sloan Research Fellowship NSF CAREER Award ONR Young Investigator Award Burroughs Wellcome Fund PATH Award Schaefer Scholar Blavatnik National Award Vilcek Prize PECASE Dr. Wang has advised numerous PhD and postdoctoral researchers, many of whom have gone on to independent scientific careers. His lab is supported by major grants from NIH, NSF, DARPA, DOE, and foundations including the Bill & Melinda Gates Foundation and CZ Biohub NY. He is actively involved in educational initiatives, including organizing Columbia’s iGEM team and the Cold Spring Harbor Laboratory Synthetic Biology course. The Wang Lab is based at the Columbia University Irving Medical Center and is part of national consortia such as the Engineering Biology Research Consortium (EBRC) and the Genome Project-Write (GP-Write) initiative. The lab develops and applies cutting-edge technologies in automation, machine learning, and synthetic biology to engineer microbiomes for applications in medicine, global health, and climate change.

Keith Alexander SharkeyView profile

Professor

• Enteric nervous system
• Gut-brain axis
• Endocannabinoid system
• +3 more

Dr. Keith Alexander Sharkey is a Professor in the Department of Physiology and Pharmacology at the Cumming School of Medicine, University of Calgary. He is also a Full Member of both the Hotchkiss Brain Institute and The Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases. Dr. Sharkey has been at the University of Calgary since his appointment as Assistant Professor in 1990, dedicating his career to understanding the neural control of the gastrointestinal tract. From 2005-2021, he held the Crohn's and Colitis Canada Chair in Inflammatory Bowel Disease Research, demonstrating his longstanding commitment to advancing knowledge in gastrointestinal sciences. Dr. Sharkey's educational journey began with a BSc (Hons) in Nutrition from the University of London in 1981, followed by a PhD in Physiology from the University of Liverpool in 1985. After completing postdoctoral training in Hungary, the UK, and Canada, he joined the University of Calgary faculty in 1990, where he has remained throughout his distinguished academic career. Dr. Sharkey's research program centers on understanding the physiology and pathophysiology of the neural control of the gastrointestinal tract and brain-gut interactions in health and disease. His laboratory investigates two main areas: the role of the endocannabinoid system in regulating GI motility and intestinal barrier function, and the physiology of the enteric nervous system in controlling motility and barrier function. His work employs state-of-the-art approaches including live cell imaging and molecular genetics. Recent publications show his expanding interest in connections between gut function and neurodegenerative conditions like ALS, with multiple 2024-2025 papers examining sexual dimorphism in disease processes and gut-brain axis mechanisms. Fellow, Royal Society of Canada (2024) Cumming School of Medicine's van de Sande Distinguished Achievement Award for Mentorship (2021) Distinguished Research Award, American Physiological Society (2021) Finkelstein Award for Excellence, Crohn's and Colitis Canada (2016) Fellow, Canadian Academy of Health Sciences (2015) Fellow, Canadian Association of Gastroenterology (2015) Killam Annual Professor Award, University of Calgary (2013) Dr. Sharkey has mentored numerous students throughout his career, as evidenced by his 2021 Mentorship Award. His research is supported by significant funding, including a CIHR Foundation grant exploring how enteric nerves and glia maintain intestinal homeostasis. He has also participated in university strategic initiatives focused on Brain and Mental Health (2015-2021) and Infections, Inflammations and Chronic Diseases (2015-2021), demonstrating his interdisciplinary approach. The Sharkey Lab provides a safe, inclusive, and diverse research environment that encourages open scientific exchange from diverse viewpoints. His laboratory is actively engaged in multiple collaborative projects, including investigations with UBC Okanagan on diet and probiotics targeting the gut-brain metabolic interactome, and with University of Calgary colleagues studying gut microbiota's role in ALS. Dr. Sharkey continues to advance our understanding of neural mechanisms controlling gastrointestinal function with upcoming courses scheduled for Fall 2024 and Winter 2025.

• Food Business Management
• Food Innovation
• Innovation Management
• +7 more

Dimitrios Skalkos serves as a Professor at the Department of Chemistry, University of Ioannina, holding the specific title of Professor of Innovation Management in Food Businesses. His office is located in building X2, room X2-206c on the Ioannina Campus (45110 Ioannina), and he leads the Food Chemistry Laboratory. He earned his Basic Degree in Chemistry from the University of Ioannina (1980-1985) followed by a Doctoral Degree from the University of Toledo, USA (1986-1989) with dissertation research on "Di- and Tetrahydroporphyrins: Syntheses and Antitumor Activities". Skalkos's research spans Food Business Management, Food Innovation, and Innovation Management, with specialized focus on Innovation & Entrepreneurship, Aromatic Plants, Innovative Foods, and Strategic Marketing. His work bridges academic research with industry applications in food systems, emphasizing Greek agricultural products and pandemic-era consumer behavior. His 36 publications (2020-2024) reveal strong trends in post-pandemic food innovation, consumer perception of traditional Greek foods, functional food development (particularly olive oil, cheese, and grape by-products), and sustainable agri-food supply chains. Key thematic clusters include traceability systems, bioactive properties of novel foods, and economic impacts on food choices. He has actively supervised Master's and PhD students through departmental presentations, directed 23 research programs, and organized 15 seminars and conferences. His laboratory website ( https://foods.chem.uoi.gr ) showcases ongoing food chemistry innovations.

• Bioelectronics
• Nanotechnology
• CMOS Technology
• +12 more

Sandro Carrara is a Full Professor at École Polytechnique Fédérale de Lausanne (EPFL), where he leads the Bio/CMOS Interfaces (BCI) laboratory. He is affiliated with the School of Engineering (STI), the Institute of Electrical Engineering (SCI-STI-SC), and the Integrated Systems Laboratory (LSI). His academic leadership spans teaching, doctoral supervision, and editorial roles in major journals including IEEE Sensors Journal and BioNanoScience. Education: Diploma in Electronics, National Technical Institute of Albenga, Italy Master in Physics, University of Genoa, Italy PhD in Biochemistry and Biophysics, University of Padua, Italy His research focuses on the integration of biological systems with CMOS technology, particularly in the development of nanoscale biosensors for health monitoring. Key areas include memristive biosensors, wearable and implantable sensors, electrochemical detection, and therapeutic drug monitoring. His work bridges electronics, nanotechnology, and biomedicine to enable point-of-care diagnostics and personalized medicine. His recent publications (2023–2025) show a strong trend toward sustainable printed electronics, machine learning for biosensing, in-memory computing for cancer diagnostics, and remote health monitoring. These works appear in high-impact journals such as IEEE Sensors Journal , Nanoscale , and Biosensors and Bioelectronics: X . Scientific Awards: IEEE Fellow (2015) IEEE Sensors Council Technical Achievement Award (2016) Distinguished Lecturer, IEEE Sensors Council (2017) Best Paper Award, IEEE MeMeA Symposium (2020) Multiple Gold and Bronze Leaf Prizes at PRIME and IEEE conferences Best Poster Awards at EMBEC and Nano-Tera meetings He actively advises PhD students and leads research projects involving CMOS-based biosensors, wireless implants, and smart sensor systems. His lab collaborates widely across disciplines and institutions, focusing on real-world applications in oncology, neurology, and environmental health. He has also contributed to the development of battery-free wearable devices, optical power transfer systems, and IoT-enabled telemedicine platforms. Laboratories and Teams: Bio/CMOS Interfaces (BCI) Laboratory, EPFL Integrated Systems Laboratory (LSI), EPFL Collaborations with IEEE Sensors Council and Circuits and Systems Society Editorial leadership in IEEE Sensors Journal and BioNanoScience

Julienne BowerView profile

Professor

• Mind-Body Interactions
• Health Psychology
• Clinical Psychology
• +7 more

Julienne Bower is a Professor at the University of California, Los Angeles (UCLA) with joint appointments in the Department of Psychology and the Department of Psychiatry/Biobehavioral Sciences. She serves as Director of the Mind-Body Research Lab, Associate Director of the Cousins Center for Psychoneuroimmunology, and as a Member of the Jonsson Comprehensive Cancer Center. Her research explores mind-body interactions in individuals facing stressful life events, particularly cancer patients and survivors, focusing on biological pathways linking psychological states to health outcomes and the effects of mind-body interventions. Ph.D. from UCLA Area Chair: Health Psychology Primary Area: Health Psychology Secondary Area: Clinical Psychology Location: 6538 Pritzker Hall, UCLA Dr. Bower's research examines how positive psychological factors (e.g., benefit finding, positive affect) influence physical health through immune and neuroendocrine pathways, while also investigating mind-body interventions like yoga and mindfulness meditation. Her work spans observational, experimental, and intervention studies, emphasizing the immune system as a central mechanism. The Mind-Body Research Lab, under Dr. Bower's leadership, has published extensively on topics including cancer-related fatigue, stress-induced inflammation, and the physiological impacts of psychosocial interventions. Key publications address NF-κB signaling, glucocorticoid resistance, and cortisol dysregulation in cancer survivors. Dr. Bower's lab is actively recruiting graduate students for 2024 through the UCLA Health Psychology Program, offering training in psychoneuroimmunology, cancer prevention, and mind-body research methodologies.

• Data Science
• Machine Learning
• Computational Harmonic Analysis
• +6 more

Pierre Vandergheynst is a Full Professor at the Swiss Federal Institute of Technology Lausanne (EPFL) in the Department of Electrical Engineering, with a courtesy appointment in Computer and Communication Sciences. He serves as EPFL’s Vice-Provost for Education since 2015 and leads the Signal Processing Laboratory 2 (LTS2). His research spans harmonic analysis, sparse approximations, mathematical data processing, and applications in signal/image processing, computer vision, machine learning, and graph-based data analysis. PhD in Mathematical Physics (1998), Université catholique de Louvain Postdoctoral Researcher at EPFL (1998-2001) Assistant Professor at EPFL (2002-2007) His research explores geometry/symmetry in high-dimensional data, redundant dictionaries for dimensionality reduction, and computational harmonic analysis on manifolds. Recent work focuses on protein structure modeling, geometric deep learning, and graph-based signal processing. Key article trends include graph neural networks for protein analysis, geometric deep learning in neuroscience, and structured knowledge priors in neural models. His 2023-2025 publications emphasize interpretable AI, long-range dependencies in graphs, and molecular representation learning. Scientific Awards: IEEE Signal Processing Magazine Best Paper Award (2023) Signal Processing Society Best Paper Award (2022) Apple ARTS Award (2007) De Boelpaepe Prize, Royal Academy of Sciences of Belgium (2009-2010) He has supervised over 30 PhD theses and contributed to foundational work in graph signal processing, compressive sensing, and geometric deep learning. His lab develops tools for data science on non-Euclidean structures, with applications in medicine, astronomy, and wireless systems.

• Natural Products Research
• Phytomedicine
• Herbal Product Standardization
• +7 more

Roles & Affiliations: Ikhlas Khan serves as Director of the National Center for Natural Products Research (NCNPR), Distinguished Professor, and Research Professor of Pharmacognosy at the University of Mississippi's School of Pharmacy. He also leads the FDA Program and coordinates natural products research across multiple initiatives, including the Sino-US TCM Research Center and the Center for Research of Indian Systems of Medicine (CRISM). Education: B.Sc. Chemistry (1980) - Aligarh Muslim University, India M.Sc. Organic Chemistry (1982) - Aligarh Muslim University, India Ph.D. Pharmacy (1987) - Ludwig-Maximilians-Universität, Munich Postdoctoral Studies - Swiss Federal Institute of Technology (ETH), Zurich Research Focus: Dr. Khan specializes in natural products research with emphasis on: Phytomedicine: Standardization of herbal products via analytical fingerprinting, pesticide/herbicide residue analysis, and bioanalytical quality control. Drug Discovery: Isolation of bioactive natural products, development of analytical methods for phytochemical characterization, and chiral separation techniques. Metabolism Studies: Role of metabolism in drug/natural product activity, particularly in aminoquinoline antimalarials. His work bridges academia, industry, and regulatory bodies, shaping policies for botanical supplements. Key Contributions: Over 850 peer-reviewed publications and leadership in high-impact projects like the FDA Center of Excellence. His lab pioneered methods to combat herbal product adulteration and safety issues. Awards & Recognition: UM Distinguished Professor Award (2018) Wiley Award (AOAC International, 2018) Qihuang International Prize (2017) Honoris Causa Doctorate (University of Hamdard, 2012) Labs & Collaborations: Directs the NCNPR, a global leader in natural products research, and collaborates with institutions worldwide. His team develops technologies for herbal product authentication and drug metabolism studies.

Allison Ross EckardView profile

Professor

• HIV-related cardiometabolic complications
• Antiretroviral therapy optimization
• Pediatric infectious diseases
• +7 more

Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.

• Iron Homeostasis
• Cell Physiology
• Systems Biology
• +4 more

Dr. Samira Lakhal-Littleton is an Associate Professor of Cell Physiology and MRC Senior Non-Clinical Research Fellow at the University of Oxford, affiliated with the Department of Physiology, Anatomy and Genetics and Brasenose College. Her research focuses on iron homeostasis, systems biology, and oxygen sensing mechanisms in cardiovascular and systemic physiology. Education: BSc in Human Genetics (University College London), DPhil in Molecular Medicine (University of Oxford) Her work bridges cell physiology and translational medicine, with key discoveries on hypoxia-inducible factors (HIFs), iron regulatory genes TMPRSS6 and GDF15 , and the role of hepcidin in altitude adaptation and chronic diseases. She utilizes tissue-specific animal models to study iron regulation in heart, kidney, placenta, and vasculature. Recent publications highlight her contributions to understanding: FLASH radiotherapy effects linked to iron-dependent lipid peroxidation Clinical implications of myocardial iron dynamics in heart failure Hepcidin's role in vascular protection and placental iron transfer Biomarker development for predictive iron deficiency diagnostics Scientific Leadership: British Heart Foundation Intermediate Fellowship (2012) MRC Senior Fellowship (2020) BioIron Society Board Member (2019) She collaborates with clinical teams on translational projects and serves as a Tutorial Fellow in Medicine at Brasenose College, mentoring students in physiological sciences.

Dennis SäringView profile

Professor

• Deep Learning
• Medical Image Analysis
• Artificial Intelligence
• +5 more

Prof. Dr. Dennis Säring is a faculty member at the University of Applied Sciences Wedel , specifically affiliated with the School of Engineering. His academic and research activities focus on Deep Learning , Medical Image Analysis , and applications of Artificial Intelligence in healthcare and biomedical imaging. He has led seminars on Deep Learning topics and supervised student projects in Autonomous Driving at Audi's AADC 2018 competition. Research Highlights : Cardiovascular imaging, forensic age estimation via MRI, neural network-based bone segmentation, and cerebrovascular aneurysm analysis. Technical Expertise : Cardiac MRI, 3D/4D image processing, parametric mapping, and spatiotemporal data fusion. His recent publications (2018-2023) emphasize 3D MR segmentation for age assessment, CMR strain analysis in athletes, and T1/T2 mapping for myocarditis. Key collaborations include institutions like the University Medical Center Hamburg-Eppendorf and Wedler Hochschulbund, with funding for autonomous vehicle research. While no explicit scientific awards are listed, his work spans clinical cardiology, forensic radiology, and AI-driven medical diagnostics.

Mark R. PittelkowView profile

Professor

• Dermatology
• Cutaneous Lymphomas
• Photoprotection
• +3 more

Mark R. Pittelkow is a Professor of Dermatology at the Mayo Clinic, holding a primary appointment as a Consultant in the Department of Dermatology. He completed his MD at Mayo Medical School and advanced training through Mayo Graduate School of Medicine and Northwestern University. His research focuses on cutaneous lymphomas, photoprotection, and skin cancer, with leadership roles in international guidelines (ISCL/EORTC). He contributes to clinical trials, medical education, and interdisciplinary research through affiliations like the Mayo Clinic Comprehensive Cancer Center and Regenerative Biotherapeutics. Education: MD (Mayo Medical School), MS (Biological Sciences, Northwestern), BA (Northwestern University). Research spans cutaneous lymphoma classification, immunology, and translational dermatology. Notable publications address staging systems for mycosis fungoides/Sezary syndrome and photoprotection strategies. His work integrates clinical practice with molecular mechanisms, such as JAK inhibitor responses in lichen planus. Labs/Teams: Collaborates with Mayo Clinic Cancer Center and interdisciplinary groups in immunotherapy and regenerative medicine. Supervises clinical trials and postdoctoral training programs.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +7 more

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

• Immunology
• Translational Immunology
• Computational Immunology
• +4 more

Professor Mark Coles serves as Professor of Immunology and Lead for Industrial Strategy and Entrepreneurship at the Kennedy Institute of Rheumatology, University of Oxford, holding concurrent roles as Kennedy Trust Senior Research Fellow, Official Fellow at Reuben College, and Affiliate Faculty at the Wolfson Centre of Mathematical Biology. His interdisciplinary work bridges immunology, computational modeling, and translational research to accelerate therapies for immune-mediated inflammatory diseases. His academic journey began with a BSc in Microbiology from Cornell University (1992), followed by a PhD in Molecular and Cell Biology at UC Berkeley under David Raulet, and postdoctoral training with Dimitris Kioussis at the National Institute of Medical Research. At the University of York (2006-2017), he pioneered stromal immunology research and co-founded the York Computational Immunology Laboratory. Coles' research centers on stromal and systems immunology, with core expertise in stromal cell biology, inflammatory disease mechanisms, and mathematical modeling of immune responses. He champions 3Rs-based approaches (Replacement, Reduction, Refinement) to reduce animal testing through in silico models, integrating spatial single-cell biology with multi-scale computational frameworks to dissect immune function in human tissues. His 2025 publications reveal a cohesive research trajectory applying interdisciplinary methods across diverse disease contexts—from cardiac fibrosis and vaccine responses to arthritis pathogenesis and CAR-T cell therapy—unified by focus on stromal-immune crosstalk and quantitative modeling to identify therapeutic targets. Key honors include: Fellow of the Royal Society of Biology Kennedy Trust Senior Research Fellow As former Director of Graduate Studies (2017-2024) at the Kennedy Institute, Coles mentored numerous graduate students while co-leading major initiatives including the Arthritis Therapy Acceleration Program and Human Cell Atlas medicalization. His entrepreneurial impact spans three co-founded ventures: Simomics Ltd (in silico disease modeling), Lightox Ltd (phototherapy for oral cancer), and Mestag Therapeutics (fibroblast-targeted therapies for cancer/inflammation). He directs the Laboratory of Stromal and Systems Immunology and Oxford Mathematical Immunology Group, fostering collaborations with Christopher Buckley, Calliope Dendrou, and Eamonn Gaffney to develop Quantitative Systems Pharmacology models that translate mechanistic insights into patient therapies.

• Pharmacology
• Traditional Chinese Medicine
• Cancer Therapy
• +7 more

Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.

Hyun KooView profile

Professor

• Biofilms
• Oral Infectious Diseases
• Nanotechnology
• +3 more

Hyun (Michel) Koo is a Professor at the University of Pennsylvania School of Dental Medicine , with affiliations in the Department of Orthodontics , Division of Community Oral Health , and Division of Pediatric Dentistry . As Co-Founder and Co-Director of the Center for Innovation & Precision Dentistry (CiPD) , he leads interdisciplinary efforts merging bioengineering, nanotechnology, and oral health research. Education : DDS and PhD Research Focus : Biofilms, bacterial-fungal interactions, and nanotechnology for oral disease prevention Leadership : Co-Director of CiPD; key roles in training programs like NIDCR-sponsored R90 and T90/R90 Dr. Koo’s research explores biofilm mechanisms in oral infectious diseases, particularly childhood caries, through engineering methods and microrobotics . His team developed micron-scale robots for automated biofilm eradication and FDA-approved nanoparticles for caries prevention. Collaborations with Penn Engineering, including Dr. Daeyeon Lee and Dr. Kacy Cullen, emphasize translational approaches. The 15 most recent publications highlight his work in nanorobotics , interkingdom biofilms , and precision diagnostics . Articles span 2025–2024 and address topics like adaptive micromotors , biofilm matrix degradation , and single-cell microbial interactions . These emphasize his focus on targeted therapies and biofilm microenvironment engineering . Key Awards : Elected Fellow, American Association for the Advancement of Science (AAAS) IADR Distinguished Scientist Award for innovative dental research Dr. Koo trains next-generation researchers through the CiPD NIDCR T90/R90 Postdoctoral Training Program , mentoring fellows like Smruti Nair (ACE2 Chewing Gum development) and Zhi Ren (K99 awardee). His work intersects with Penn Health-Tech, CT3N , and Penn Institute for Biomedical Informatics , fostering transdisciplinary innovation.